CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery

Novo Nordisk unveils weight-loss data from REDEFINE 4 trial

CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026

200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities

BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal